Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G versus TERCONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G versus TERCONAZOLE.
FULVICIN P/G vs TERCONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubule-associated proteins, disrupting mitotic spindle formation and inhibiting fungal cell division.
Terconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and function.
250 mg orally twice daily for tinea infections; 500 mg orally twice daily for onychomycosis. Administer with a fatty meal to enhance absorption.
Intravaginal cream (0.4%, 0.8%): one applicatorful (approximately 5 g) intravaginally once daily at bedtime for 7 days; vaginal suppository (80 mg): one suppository intravaginally once daily at bedtime for 3 days.
None Documented
None Documented
Clinical Note
moderateTerconazole + Tranilast
"The risk or severity of adverse effects can be increased when Terconazole is combined with Tranilast."
Clinical Note
moderateTerconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Terconazole is combined with Tolfenamic acid."
Clinical Note
moderateTerconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Terconazole is combined with Nimesulide."
Clinical Note
moderateTerconazole + Risedronic acid
Terminal elimination half-life: 9–24 hours (mean ~16 hours). Clinical context: prolonged half-life allows once-daily dosing; steady-state achieved within 2–3 days.
Terminal elimination half-life is approximately 25-37 hours, allowing once-daily dosing for vaginal infections.
Renal (largely unchanged, <1% as metabolites); biliary/fecal (minor). Approximately 36% of a dose is excreted in urine within 6 hours, and up to 50% within 72 hours.
Primarily hepatic metabolism with biliary excretion; approximately 60-80% of the dose is excreted in feces as metabolites, and about 20% in urine mostly as inactive metabolites.
Category C
Category A/B
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Terconazole is combined with Risedronic acid."